Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Phase Ⅱ Multicenter Clinical Trial From China

NCT06530576 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT06530576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06530576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Phase Ⅱ Multicenter Clinical Trial From China
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2
Overall status
Recruiting
Start date
August 10, 2024
Completion date
July 1, 2027
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nk-lgl leukemia, t-lgl leukemia